Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ARWRNASDAQ:SUPNNASDAQ:VBLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$26.30+3.1%$19.91$16.50▼$26.50$2.29BN/A77,698 shs41,147 shsARWRArrowhead Pharmaceuticals$13.25-0.7%$14.72$9.57▼$30.41$1.82B0.991.44 million shs862,735 shsSUPNSupernus Pharmaceuticals$32.22+2.8%$32.09$25.53▼$40.28$1.80B0.9494,780 shs356,067 shsVBLTVascular Biogenics$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+6.69%+36.22%+38.14%+2,549,999,900.00%+2,549,999,900.00%ARWRArrowhead Pharmaceuticals+2.54%+18.68%-9.44%-35.74%-42.72%SUPNSupernus Pharmaceuticals+1.65%+1.92%-5.14%-18.68%+3.60%VBLTVascular Biogenics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AARWRArrowhead Pharmaceuticals3.47 of 5 stars3.31.00.03.43.42.50.0SUPNSupernus Pharmaceuticals3.0874 of 5 stars2.23.00.04.13.80.80.0VBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AARWRArrowhead Pharmaceuticals 2.60Moderate Buy$41.44212.79% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0011.73% UpsideVBLTVascular Biogenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VBLT, SUPN, AAPG, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025AAPGAscentage Pharma Group InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight2/26/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $36.002/19/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$57.00 ➝ $36.002/14/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $38.002/12/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.002/11/2025ARWRArrowhead PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.002/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.34N/AN/AN/A∞ARWRArrowhead Pharmaceuticals$2.50M727.78N/AN/A$1.54 per share8.60SUPNSupernus Pharmaceuticals$661.82M2.72$1.48 per share21.83$16.87 per share1.91VBLTVascular Biogenics$660K0.00N/AN/A$0.32 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AARWRArrowhead Pharmaceuticals-$599.49M-$5.17N/AN/AN/AN/A-236.60%-64.09%5/8/2025 (Estimated)SUPNSupernus Pharmaceuticals$1.32M$1.3230.1122.38N/A9.16%7.79%5.67%5/6/2025 (Estimated)VBLTVascular Biogenics-$32.30M-$0.21N/AN/AN/AN/A-73.45%-54.11%N/ALatest VBLT, SUPN, AAPG, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SUPNSupernus Pharmaceuticals$0.37N/AN/AN/AN/AN/A5/8/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06N/AN/AN/A$116.27 millionN/A2/10/2025Q1 2025ARWRArrowhead Pharmaceuticals-$0.42-$1.39-$0.97-$1.39$19.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AARWRArrowhead Pharmaceuticals7.276.096.09SUPNSupernus PharmaceuticalsN/A2.201.98VBLTVascular BiogenicsN/A4.634.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AARWRArrowhead Pharmaceuticals62.61%SUPNSupernus PharmaceuticalsN/AVBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AARWRArrowhead Pharmaceuticals4.30%SUPNSupernus Pharmaceuticals9.30%VBLTVascular Biogenics6.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.07 millionN/AN/AARWRArrowhead Pharmaceuticals400137.32 million120.68 millionOptionableSUPNSupernus Pharmaceuticals58055.81 million50.08 millionOptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableVBLT, SUPN, AAPG, and ARWR HeadlinesRecent News About These CompaniesVBL warns of financial impact of severance payments in second pillar reformSeptember 4, 2024 | ipe.comMarket Unimpressed By VBL's 26% Jump In Net Profit, Shares Tank 5%July 30, 2024 | msn.comTom Sox move one step closer to VBL title with 7-5 win over PurcellvilleJuly 30, 2024 | cbs19news.comTom Sox drop game one of the VBL South Division Series against Cavaliers, 4-1July 26, 2024 | cbs19news.comBenign and Malignant Vascular Tumors of the Liver in AdultsMay 23, 2024 | medscape.comVBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To ComeMay 14, 2024 | msn.comAlboGraft Polyester Vascular Graft from LeMaitreMay 7, 2024 | news-medical.netTommy Garten elected to VBL Hall of FameMarch 28, 2024 | therecorderonline.comControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemFebruary 21, 2024 | nature.comVascular News and ResearchNovember 25, 2023 | news-medical.netVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26November 3, 2023 | msn.comNotable Labs Closes Merger Transaction With VBL TherapeuticsOctober 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingOctober 12, 2023 | finance.yahoo.comVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingOctober 4, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeSeptember 9, 2023 | finance.yahoo.comVBLT Stock Sees Decline of Approximately -0.22% in Last Five DaysSeptember 7, 2023 | knoxdaily.comVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECSeptember 6, 2023 | finance.yahoo.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVBLT, SUPN, AAPG, and ARWR Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$26.30 +0.80 (+3.14%) As of 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Arrowhead Pharmaceuticals NASDAQ:ARWR$13.25 -0.09 (-0.67%) Closing price 04:00 PM EasternExtended Trading$13.24 -0.02 (-0.11%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Supernus Pharmaceuticals NASDAQ:SUPN$32.22 +0.87 (+2.78%) Closing price 04:00 PM EasternExtended Trading$30.30 -1.93 (-5.97%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.Vascular Biogenics NASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
